Nuvation Bio Inc. (NYSE:NUVB) Receives $12.50 Consensus Price Target from Analysts

Nuvation Bio Inc. (NYSE:NUVB) has received a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $12.50.

A number of brokerages have commented on NUVB. Zacks Research lowered Nuvation Bio from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. UBS Group decreased their price objective on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 3rd. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a research report on Tuesday, May 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Nuvation Bio in a research report on Tuesday, May 5th.

Nuvation Bio Stock Down 0.8%

NYSE NUVB opened at $5.61 on Monday. The firm has a market cap of $1.95 billion, a PE ratio of -13.03 and a beta of 1.52. Nuvation Bio has a one year low of $1.87 and a one year high of $9.75. The stock’s 50 day simple moving average is $4.94 and its 200 day simple moving average is $5.70. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.44 and a quick ratio of 7.24.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. The firm had revenue of $83.23 million for the quarter, compared to analyst estimates of $66.22 million. Nuvation Bio had a negative return on equity of 44.10% and a negative net margin of 102.06%. As a group, sell-side analysts forecast that Nuvation Bio will post -0.39 earnings per share for the current fiscal year.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, insider Stacy Markel sold 125,000 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.03, for a total value of $753,750.00. Following the transaction, the insider directly owned 32,591 shares in the company, valued at approximately $196,523.73. This trade represents a 79.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dongfang Liu sold 50,000 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $5.02, for a total value of $251,000.00. Following the completion of the transaction, the insider directly owned 18,000 shares in the company, valued at approximately $90,360. This trade represents a 73.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 522,418 shares of company stock worth $2,758,612. Corporate insiders own 30.11% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NUVB. Rangeley Capital LLC acquired a new position in shares of Nuvation Bio in the 2nd quarter valued at $25,000. Parallel Advisors LLC lifted its stake in shares of Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after purchasing an additional 2,597 shares during the period. Cetera Investment Advisers acquired a new position in shares of Nuvation Bio in the 2nd quarter valued at $29,000. Captrust Financial Advisors acquired a new position in shares of Nuvation Bio in the 2nd quarter valued at $32,000. Finally, KBC Group NV acquired a new position in shares of Nuvation Bio in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.